{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:13:25Z","timestamp":1793330005450,"version":"4.5.0"},"reference-count":42,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Special Projects in Key Fields of Ordinary Colleges and Universities in Guangdong Province","award":["2020KCXTD021"],"award-info":[{"award-number":["2020KCXTD021"]}]},{"name":"Special Projects in Key Fields of Ordinary Colleges and Universities in Guangdong Province","award":["2024ZDZX2057"],"award-info":[{"award-number":["2024ZDZX2057"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010412"],"award-info":[{"award-number":["2023A1515010412"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773720"],"award-info":[{"award-number":["81773720"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473920"],"award-info":[{"award-number":["82473920"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diabetic cardiomyopathy (DCM), characterized by myocardial hypertrophy and fibrosis, is a severe complication of diabetes. Activation of Yes-associated protein (Yap) has been implicated in myocardial remodeling and cardiac dysfunction. This study aimed to elucidate the role and underlying molecular mechanisms of Yap in DCM. Yap expression was evaluated in mice with type 2 diabetes mellitus (T2DM) and in neonatal rat cardiomyocytes (NRCMs) treated with high glucose (HG) or HG + palmitic acid (PA). Adeno-associated virus transfection, adenovirus infection, and a transgenic mouse model were used to modulate Yap expression both in\u00a0vivo and in\u00a0vitro. RNA sequencing and miRNA sequencing were used to identify Yap\u2019s downstream targets and related mechanisms. Functional assays, including assessment of molecular markers, cell morphology, and echocardiography, were conducted to evaluate cardiomyocyte hypertrophy and fibrosis. Results showed that Yap expression was elevated in HG or HG+PA-treated NRCMs and hearts of T2DM mice, promoting myocardial hypertrophy and fibrosis. Inhibition of Yap reduced cardiomyocyte cross-sectional area, collagen deposition, and levels of hypertrophy markers atrial natriuretic peptide and \u03b2-myosin heavy chain. RNA sequencing identified Sirt1 as a downstream target of Yap. Bioinformatics analysis indicated that Yap positively regulated miR-22-3p, which in turn inhibited Sirt1. Yap inhibition increased Sirt1 expression, alleviating myocardial remodeling. Conversely, Sirt1 knockdown reversed the protective effects of Yap inhibition, exacerbating hypertrophy and fibrosis. In conclusion, Yap promotes the progression of DCM by upregulating miR-22-3p expression and suppressing Sirt1 expression. Therapeutically targeting the newly identified Yap\u2013miR-22-3p\u2013Sirt1 axis could mitigate multiple aspects of diabetic cardiac remodeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Article Highlights<\/jats:title>\n                    <jats:p>Diabetic cardiomyopathy (DCM) describes the abnormality of myocardial structure and function caused by diabetes, and Yes-associated protein (Yap) is linked to various cardiovascular diseases, modulating remodeling and cardiac function in hearts, but its role in DCM is unclear. How Yap affects myocardial structure and function in mice with type 2 diabetes mellitus and the underlying pathways were investigated. High glucose or high glucose plus palmitic acid levels enhance Yap activity, thereby promoting miR-22-3p expression and inhibiting sirtuin 1 (Sirt1) expression. The Yap\u2013miR-22-3p\u2013Sirt1 axis plays critical roles in the cause of DCM. The molecular pathways investigated offer promising targets for therapeutic intervention against DCM and provide new insights into the development of innovative treatment strategies to combat cardiac dysfunction in patients with diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db25-0435","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:52:36Z","timestamp":1772463156000},"page":"974-990","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling Diabetic Cardiomyopathy (DCM): The Critical Role of the Yap\u2013miR-22-3p\u2013Sirt1 Axis in the Pathogenesis of DCM"],"prefix":"10.2337","volume":"75","author":[{"given":"Yilang","family":"Li","sequence":"first","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zeng","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Lian","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipu","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ducai","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongying","family":"Shi","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangzhou Medical University 2 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-1154","authenticated-orcid":false,"given":"Xun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-4946","authenticated-orcid":false,"given":"Ning","family":"Hou","sequence":"additional","affiliation":[{"name":"Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University 1 , Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026061712323840700_B1","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Care in Diabetes\u20142023","volume":"46","author":"American Diabetes Association","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061712323840700_B2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","article-title":"Genetics of diabetes mellitus and diabetes complications","volume":"16","author":"Cole","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026061712323840700_B3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ Res"},{"key":"2026061712323840700_B4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"2026061712323840700_B5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu Rev Biochem"},{"key":"2026061712323840700_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.274027.115","article-title":"Mechanisms of Hippo pathway regulation","volume":"30","author":"Meng","year":"2016","journal-title":"Genes Dev"},{"key":"2026061712323840700_B7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.devcel.2020.06.025","article-title":"Integration of Hippo-YAP signaling with metabolism","volume":"54","author":"Ibar","year":"2020","journal-title":"Dev Cell"},{"key":"2026061712323840700_B8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1161\/CIRCRESAHA.116.303311","article-title":"The Hippo pathway in heart development, regeneration, and diseases","volume":"116","author":"Zhou","year":"2015","journal-title":"Circ Res"},{"key":"2026061712323840700_B9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fcell.2019.00211","article-title":"The Hippo signaling pathway in cardiac development and diseases","volume":"7","author":"Mia","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"2026061712323840700_B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nature20602","article-title":"Integrin-YAP\/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow","volume":"540","author":"Wang","year":"2016","journal-title":"Nature"},{"key":"2026061712323840700_B11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00395-014-0435-8","article-title":"The alteration of Hippo\/YAP signaling in the development of hypertrophic cardiomyopathy","volume":"109","author":"Wang","year":"2014","journal-title":"Basic Res Cardiol"},{"key":"2026061712323840700_B12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.biopha.2017.03.056","article-title":"The role of SIRT1 in diabetic cardiomyopathy","volume":"90","author":"Karbasforooshan","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026061712323840700_B13","doi-asserted-by":"crossref","first-page":"4602715","DOI":"10.1155\/2017\/4602715","article-title":"SIRT1 activation by resveratrol alleviates cardiac dysfunction via mitochondrial regulation in diabetic cardiomyopathy mice","volume":"2017","author":"Ma","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2026061712323840700_B14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2337\/db21-0506","article-title":"Methazolamide attenuates the development of diabetic cardiomyopathy by promoting \u03b2-catenin degradation in type 1 diabetic mice","volume":"71","author":"Chen","year":"2022","journal-title":"Diabetes"},{"key":"2026061712323840700_B15","doi-asserted-by":"crossref","first-page":"e001478","DOI":"10.1136\/bmjdrc-2020-001478","article-title":"Metabolic and energetic benefits of microRNA-22 inhibition","volume":"8","author":"Thibonnier","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061712323840700_B16","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1002\/mco2.340","article-title":"YAP\/TAZ: molecular pathway and disease therapy","volume":"4","author":"Wei","year":"2023","journal-title":"MedComm (2020)"},{"key":"2026061712323840700_B17","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1021\/bi2001888","article-title":"Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway","volume":"50","author":"Webb","year":"2011","journal-title":"Biochemistry"},{"key":"2026061712323840700_B18","doi-asserted-by":"crossref","first-page":"971416","DOI":"10.3389\/fimmu.2022.971416","article-title":"The Hippo-YAP pathway in various cardiovascular diseases: focusing on the inflammatory response","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"2026061712323840700_B19","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1161\/CIRCRESAHA.120.315899","article-title":"Metabolic and molecular imaging of the diabetic cardiomyopathy","volume":"126","author":"Peterson","year":"2020","journal-title":"Circ Res"},{"key":"2026061712323840700_B20","doi-asserted-by":"crossref","first-page":"106014","DOI":"10.1016\/j.phrs.2021.106014","article-title":"SIRT1-FOXOs activity regulates diabetic complications","volume":"175","author":"Jalgaonkar","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026061712323840700_B21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.atherosclerosis.2017.08.027","article-title":"The sirtuin family members SIRT1, SIRT3 and SIRT6: their role in vascular biology and atherogenesis","volume":"265","author":"Sosnowska","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026061712323840700_B22","doi-asserted-by":"crossref","first-page":"6746907","DOI":"10.1155\/2019\/6746907","article-title":"Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway","volume":"2019","author":"Li","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"2026061712323840700_B23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/aps.2017.50","article-title":"Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1\u03b1 deacetylation","volume":"39","author":"Fang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"2026061712323840700_B24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCRESAHA.118.312498","article-title":"Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular diseases","volume":"123","author":"Kane","year":"2018","journal-title":"Circ Res"},{"key":"2026061712323840700_B25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molmed.2021.03.004","article-title":"Sirtuins: to be or not to be in diabetic cardiomyopathy","volume":"27","author":"Palomer","year":"2021","journal-title":"Trends Mol Med"},{"key":"2026061712323840700_B26","doi-asserted-by":"crossref","first-page":"808480","DOI":"10.3389\/fphar.2021.808480","article-title":"Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1\/Nrf2 signaling pathway activation","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026061712323840700_B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/nyas.12812","article-title":"The effects of resveratrol and SIRT1 activation on dystrophic cardiomyopathy","volume":"1348","author":"Kuno","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"2026061712323840700_B28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/biomedicines9010052","article-title":"SIRT1 activation attenuates the cardiac dysfunction induced by endothelial cell-specific deletion of CRIF1","volume":"9","author":"Piao","year":"2021","journal-title":"Biomedicines"},{"key":"2026061712323840700_B29","first-page":"1671","article-title":"Yap regulates gastric cancer survival and migration via SIRT1\/Mfn2\/mitophagy","volume":"39","author":"Yan","year":"2018","journal-title":"Oncol Rep"},{"key":"2026061712323840700_B30","doi-asserted-by":"crossref","first-page":"e13471","DOI":"10.1111\/1753-0407.13471","article-title":"CircMAP3K5 promotes cardiomyocyte apoptosis in diabetic cardiomyopathy by regulating miR-22-3p\/DAPK2 Axis","volume":"16","author":"Shen","year":"2024","journal-title":"J Diabetes"},{"key":"2026061712323840700_B31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4103\/1673-5374.211172","article-title":"Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathways","volume":"12","author":"Castelnovo","year":"2017","journal-title":"Neural Regen Res"},{"key":"2026061712323840700_B32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","article-title":"The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells","volume":"147","author":"Cordenonsi","year":"2011","journal-title":"Cell"},{"key":"2026061712323840700_B33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.03.018","article-title":"Dysregulation of the Hippo pathway signaling in aging and cancer","volume":"143","author":"Yeung","year":"2019","journal-title":"Pharmacol Res"},{"key":"2026061712323840700_B34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41419-021-04338-8","article-title":"ARSD, a novel ER\u03b1 downstream target gene, inhibits proliferation and migration of breast cancer cells via activating Hippo\/YAP pathway","volume":"12","author":"Lin","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026061712323840700_B35","doi-asserted-by":"crossref","first-page":"109198","DOI":"10.1016\/j.abb.2022.109198","article-title":"YAP1 induces hyperglycemic stress-mediated cardiac hypertrophy and fibrosis in an AKT-FOXM1 dependent signaling pathway","volume":"722","author":"Mondal","year":"2022","journal-title":"Arch Biochem Biophys"},{"key":"2026061712323840700_B36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41419-021-04164-y","article-title":"Corosolic acid inhibits cancer progression by decreasing the level of CDK19-mediated O-GlcNAcylation in liver cancer cells","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis"},{"key":"2026061712323840700_B37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bbrc.2019.03.158","article-title":"Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP\/TAZ signaling","volume":"512","author":"Wu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"2026061712323840700_B38","doi-asserted-by":"crossref","first-page":"112152","DOI":"10.1016\/j.biopha.2021.112152","article-title":"Icariin attenuates bleomycin-induced pulmonary fibrosis by targeting Hippo\/YAP pathway","volume":"143","author":"Du","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026061712323840700_B39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/neuonc\/noab244","article-title":"Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models","volume":"24","author":"Barrette","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026061712323840700_B40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","article-title":"A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer","volume":"25","author":"Jiao","year":"2014","journal-title":"Cancer Cell"},{"key":"2026061712323840700_B41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1535-7163.MCT-17-0560","article-title":"A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma","volume":"17","author":"Song","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026061712323840700_B42","first-page":"1158","article-title":"Sirtuin-targeting drugs: mechanisms of action and potential therapeutic applications","volume":"11","author":"Aljada","year":"2010","journal-title":"Curr Opin Investig Drugs"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/6\/974\/857692\/db250435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/75\/6\/974\/857692\/db250435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:32:46Z","timestamp":1781713966000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/6\/974\/164518\/Unraveling-Diabetic-Cardiomyopathy-DCM-The"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db25-0435","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}